个人简介 ——

倪静，女，医学博士，副主任医师，精通妇科常见恶性肿瘤的诊治及进展，擅长妇科恶性肿瘤的手术（包括微创手术）、化疗、靶向治疗、免疫治疗等综合治疗，主持国家自然科学基金青年基金、江苏省青年自然科学基金及江苏省妇幼健康科研重点项目，获得江苏省卫健委新技术引进奖一等奖，参与国自然面上项目一项，发表本专业领域SCI论文13篇，总影响因子60余分。获得本专业相关发明专利一项。

科研方向 ——

卵巢癌综合诊治及其耐药的机制研究。

发表文章 ——

1.Jing Ni, Qian Zhao, Xianzhong Cheng, Xia Xu, Wenwen Guo, Rui Zhou, Hongyuan Gu, Chen Chen, Xiaoxiang Chen. Homologous recombination deficiency Associated with Response to Poly (ADP-ribose) polymerase inhibitors in ovarian cancer patients: the first real-word data from China. Front Oncol. DOI: 10.3389/fonc.2021.746571
2.Wenwen Guo#, Xue He#, Jing Ni#, Liya Ma, Xianzhong Cheng, Congyang Wang, Xiaoxiang Chen, Yan Wang. High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis. Front Oncol. doi: 10.3389/fonc.2021.761960.
3.Jing Ni, Xianzhong Cheng, Rui Zhou, Qian Zhao, Xia Xu, Wenwen Guo, Hongyuan Gu, Chen Chen, Xiaoxiang Chen. Adverse events as a potential clinical marker of antitumor efficacy in ovarian cancer patients treated with poly ADP-ribose polymerase(PARP) inhibitor. Front Oncol. doi: 10.3389/fonc.2021.724620.
4.Xianzhong Cheng, Qian Zhao, Xia Xu, Wenwen Guo, Hongyuan Gu, Rui Zhou, Chen Chen, Dawei Ma, Yinan Wu, Jing Ni*, Xiaoxiang Chen*. Extragonadal Yolk Sac Tumors Originating From the Endometrium and the Broad Ligament: A Case Series and Literature Review. Front Oncol. 2021;11:672434.
5.Jing Ni, Xianzhong Cheng, Qian Zhao, Zhiqin Dai, Xia Xu, Wenwen Guo, Hongyuan Gu, Rui Zhou, Yan Wang, Xiaoxiang Chen. The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. J Ovarian Res. 2021;14(1):68.
6.Jing Ni, Hongyuan Gu, Rui zhou, Xianzhong Cheng, Bifang Zhou, Wenwen Guo, Yan Wang, Xiaoxiang Chen. 8-OHdG Repair is Associated with Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma. Eur J Gynaecol Oncol. DOI:10.31083/j.ejgo.2021.02.2105
7.Jing Ni, Yan Wang, Xianzhong Cheng, Fang Teng, Congyang Wang, Suping Han, Xiaoxiang Chen, Wenwen Guo. Pathogenic Heteroplasmic Somatic Mitochondrial DNA Mutation Confers Platinum-Resistance and Recurrence of High-Grade Serous Ovarian Cancer. Cancer Manag Res. 2020,12:11085–11093.
8.Jing Ni, Xianzhong Cheng, Jin Chen, Wenwen Guo, Zhiqin Dai. Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety. Onco Targets Ther. 2020,13:9857–9863.
9.Jing Ni#, Rui Zhou#, Xianzhong Cheng, Xia Xu, Wenwen Guo, Xiaoxiang Chen. Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series. J Ovarian Res. 2020,17;13(1):29.
10.Hongyuan Gu#, Rui Zhou#, Jing Ni#, Xia Xu, Xianzhong Cheng , Yan Li , Xiaoxiang Chen. The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial. J Ovarian Res.2020, 16;13(1):70.
11.Jing Ni#, Xianzhong Cheng#, Rui Zhou, Xia Xu, Wenwen Guo, Xiaoxiang Chen. Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China. J Ovarian Res. 2019, 28;12(1):117.
12.倪静,郭文文,滕芳,程贤中,陈小祥,交界性卵巢肿瘤临床病理特征及术式和复发相关因素分析.中国卫生检验杂志,2018,28(24):3044-3048.
13.Hua Jin#, Xiaoyun Lu#, Jing Ni#, Jinfang Sun, Bin Gu, Bo Ding, Haixia Zhu, Chao Ma, Mengjing Cui, Yuling Xu, Zhengdong Zhang, Martin Lercher, Jian Chen, Na Gao, Shizhi Wang. HOTAIR rs7958904 polymorphism is associated with increased cervical cancer risk in a Chinese population, Sci Rep. 2017, 7(1): 3144.
14. Jing Ni, Qiang Wu, Zhi-Hua Sun, Jian Zhong, Yu Cai, Xin-En Huang. The Inhibition Effect of Triptolide on Human Endometrial Carcinoma Cell Line HEC-1B: a in vitro and in vivo Studies. Asian Pac J Cancer Prev. 2015;16(11):4571-6.